Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 23, 2008

Inovio Wins $933K Biodefense Contract for DNA Vaccine Development

  • Inovio Biomedical received $933,000 from the DoD to advance DNA-based vaccines delivered via its electroporation system. The contract will run through May 2010.

    The project focuses on identifying DNA vaccine candidates with the potential to provide rapid, robust immunity to protect against biowarfare and bioterror attacks.

    In October 2006, the DoD awarded Inovio $1.1 million to develop its electroporation-based gene delivery technology. The aim was to be able to use this technology in vaccinations against infectious diseases resulting from potential bioterrorism agents.

    Inovio president and CEO, Avtar Dhillon, M.D., points out that “knowledge developed from this research is also relevant to the research and development of commercially attractive therapeutic vaccines for targets such as cancer and chronic infectious diseases.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »